Table 3 Univariate and multivariate analysis of prognostic factors in patients with (OS)
Parameters | Median (months) | 95% CI | P value | Hazard ratio | 95% CI | P value |
|---|---|---|---|---|---|---|
Age | .285 | – | ||||
≦65 (n = 74) | 10.0 | 8.0–12.0 | ||||
> 65 (n = 44) | 6.9 | 5.4–8.3 | ||||
Gender | .028 | |||||
Male (n = 58) | 6.1 | 3.6–8.6 | 1.782 | 1.151–2.759 | .010 | |
Female (n = 60) | 11.0 | 9.1–12.9 | 1 | |||
ICD-10 cancer site | .143 | – | ||||
C22.1 – ICCA (n = 86) | 8.7 | 6.6–10.9 | ||||
C23/C24.9 –GB/others (n = 18) | 6.1 | 4.5–7.8 | ||||
C24.0 – ECCA (n = 9) | 10.0 | 3.3–16.7 | ||||
C24.1 – Ampullary (n = 5) | 12.5 | 8.5–16.6 | ||||
Performance status | .006 | |||||
0/1 (n = 102) | 9.0 | 7.2–10.8 | 1 | |||
2/3 (n = 16) | 3.2 | 0.0–7.6 | 1.089 | 0.568–2.084 | .798 | |
NLR | .032 | |||||
≦7.45 (n = 100) | 8.9 | 6.8–11.1 | 1 | |||
> 7.45 (n = 18) | 2.7 | 0.0–7.6 | 1.922 | 1.009–3.663 | .047 | |
MLR | .005 | |||||
≦0.28 (n = 40) | 12.5 | 11.1–13.9 | 1 | |||
> 0.28 (n = 78) | 5.9 | 3.6–8.3 | 1.359 | 0.793–2.328 | .264 | |
PLR | .839 | – | ||||
≦136.4 (n = 47) | 9.8 | 7.4–12.1 | ||||
> 136.4 (n = 71) | 7.7 | 6.1–9.3 | ||||
Albumin (g/dL) | .244 | – | ||||
≦3.5 (n = 33) | 5.9 | 2.0–9.8 | ||||
> 3.5 (n = 72) | 9.7 | 6.8–12.6 | ||||
ALT (U/L) | .819 | – | ||||
≦36 (n = 68) | 8.1 | 6.7–9.8 | ||||
> 36 (n = 49) | 9.0 | 5.7–12.3 | ||||
Bilirubin (mg/dL) | .696 | – | ||||
≦1.3 (n = 89) | 9.7 | 7.7–11.7 | ||||
> 1.3 (n = 28) | 7.5 | 5.6–9.3 | ||||
ALP (U/L) | .007 | |||||
≦94 (n = 30) | 13.1 | 10.2–16.1 | 1 | |||
> 94 (n = 82) | 6.3 | 4.2–8.3 | 2.523 | 1.470–4.331 | .001 | |
Creatinine (mg/dL) | .244 | – | ||||
≦1.27 (n = 115) | 8.7 | 6.9–10.5 | ||||
> 1.27 (n = 3) | 3.2 | 0.0–8.0 | ||||
CA19–9 (U/mL) | .206 | – | ||||
≦37 (n = 35) | 6.3 | 4.5–8.0 | ||||
> 37 (n = 82) | 9.7 | 7.3–12.1 | ||||
CEA (ng/mL) | .358 | – | ||||
≦5 (n = 64) | 9.0 | 6.4–11.6 | ||||
> 5 (n = 54) | 7.7 | 5.9–9.5 | ||||
Biliary drainage | .045 | |||||
None (n = 88) | 8.4 | 6.2–10.5 | 2.041 | 0.708–5.883 | .187 | |
Internal drainage (n = 8) | 22.7 | 2.1–43.3 | 1 | |||
PTCD (n = 19) | 7.5 | 5.2–9.7 | 1.559 | 0.500–4.861 | .444 | |
Both (n = 3) | 4.5 | 0.0–10.5 | 6.024 | 1.253–28.969 | .025 | |
Tumor involvement | ||||||
Primary | .612 | – | ||||
No (n = 8) | 10.1 | 7.5–12.6 | ||||
Yes (n = 100) | 8.1 | 6.2–10.0 | ||||
Regional LAP | .265 | – | ||||
No (n = 42) | 11.7 | 6.2–17.3 | ||||
Yes (n = 76) | 7.7 | 6.3–9.1 | ||||
Lung | .009 | |||||
No (n = 95) | 10.0 | 8.1–11.9 | 1 | |||
Yes (n = 23) | 6.3 | 3.3–9.2 | 0.681 | 0.367–1.263 | .223 | |
Bone | .330 | – | ||||
No (n = 105) | 8.9 | 6.8–11.1 | ||||
Yes (n = 13) | 5.1 | 3.7–6.5 | ||||
Liver | .246 | – | ||||
No (n = 69) | 9.0 | 7.2–10.8 | ||||
Yes (n = 49) | 7.7 | 4.6–10.7 | ||||
Peritoneum | .032 | |||||
No (n = 96) | 8.9 | 6.2–11.7 | 1 | |||
Yes (n = 22) | 5.9 | 0.3–11.5 | 1.712 | 0.996–2.944 | .052 | |
Distant LAP | .408 | – | ||||
No (n = 102) | 8.9 | 6.7–11.2 | ||||
Yes (n = 16) | 6.3 | 3.0–9.6 | ||||
Tumor Response | <.0001 | |||||
CR/RR (n = 15) | 21.9 | 11.6–32.2 | 1 | |||
SD (n = 41) | 12.2 | 10.7–13.7 | 2.430 | 1.012–5.838 | .047 | |
PD (n = 48) | 6.1 | 4.3–8.0 | 10.994 | 4.397–27.489 | <.0001 | |
N/A (n = 14) | 1.3 | 0.8–1.9 | 109.903 | 33.541–360.113 | <.0001 | |